Kazia Therapeutics Net debt/EBITDA
Quel est le Net debt/EBITDA de Kazia Therapeutics?
Le Net debt/EBITDA de Kazia Therapeutics Limited est 0.58
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics
Que fait Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Entreprises avec net debt/ebitda similaire à Kazia Therapeutics
- Johnson Service PLC a Net debt/EBITDA de 0.58
- Facedrive a Net debt/EBITDA de 0.58
- Steer Technologies Inc a Net debt/EBITDA de 0.58
- KNT a Net debt/EBITDA de 0.58
- Aris Gold a Net debt/EBITDA de 0.58
- Generix SA a Net debt/EBITDA de 0.58
- Kazia Therapeutics a Net debt/EBITDA de 0.58
- Auto Trader Plc a Net debt/EBITDA de 0.58
- Sinotrans a Net debt/EBITDA de 0.58
- Copper Lake Resources a Net debt/EBITDA de 0.58
- Core One Labs a Net debt/EBITDA de 0.58
- Oeneo SA a Net debt/EBITDA de 0.58
- Oeneo SA a Net debt/EBITDA de 0.58